ストックスクリーナーアプリを入手
14.55
0.55%
-0.08
前日終値:
$14.63
開ける：
$14.63
24時間の取引高:
108.44K
Relative Volume:
0.60
時価総額：
$422.23M
収益：
$66.98M
当期純損益:
$-71.54M
株価収益率:
-4.5408
EPS:
-3.2043
ネットキャッシュフロー:
$-18.46M
1週間 パフォーマンス:
+5.66%
1か月 パフォーマンス:
+14.57%
6か月 パフォーマンス:
+24.57%
1年 パフォーマンス:
+182.52%
1日の値動き範囲:
$14.33
$14.89
1週間の範囲:
$13.29
$14.89
52週間の値動き範囲:
$4.73
$17.15
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
名前
Enanta Pharmaceuticals Inc
セクター
電話
617 607 0800
住所
4 KINGSBURY AVENUE, WATERTOWN, MA
Compare ENTA vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
14.55 | 424.55M | 66.98M | -71.54M | -18.46M | -3.2043 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-26 | 開始されました | Rodman & Renshaw | Buy |
| 2025-11-14 | 開始されました | JP Morgan | Overweight |
| 2025-10-01 | アップグレード | Jefferies | Hold → Buy |
| 2025-07-28 | 再開されました | H.C. Wainwright | Buy |
| 2023-08-09 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-08-08 | ダウングレード | Jefferies | Buy → Hold |
| 2022-12-09 | 開始されました | H.C. Wainwright | Buy |
| 2022-07-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2022-06-01 | アップグレード | Evercore ISI | Underperform → In-line |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-09-09 | 開始されました | SVB Leerink | Mkt Perform |
| 2021-01-29 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-11-24 | 開始されました | Evercore ISI | Underperform |
| 2020-08-28 | 再開されました | ROTH Capital | Buy |
| 2020-08-26 | 開始されました | Piper Sandler | Overweight |
| 2020-07-27 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2019-05-24 | 開始されました | Wolfe Research | Outperform |
| 2019-04-23 | アップグレード | Berenberg | Hold → Buy |
| 2018-12-13 | 開始されました | Berenberg | Hold |
| 2018-06-06 | 開始されました | ROTH Capital | Buy |
| 2018-02-08 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-01-02 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-07-11 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 繰り返されました | Barclays | Underweight |
| 2015-10-23 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2015-10-23 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
すべてを表示
Enanta Pharmaceuticals Inc (ENTA) 最新ニュース
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Above 50-Day Moving AverageHere's Why - MarketBeat
Enanta (ENTA) Begins Phase 1 Trial for EDP-978 - GuruFocus
Enanta doses first patient in phase 1 trial of urticaria drug - Investing.com Australia
Gains Report: Should I trade or invest in Enanta Pharmaceuticals IncEarnings Summary Report & Weekly Setup with High ROI Potential - baoquankhu1.vn
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria - BioSpace
Enanta Pharmaceuticals Initiates Phase 1 Trial of EDP-978 in Chronic Urticaria - marketscreener.com
Meme Stocks: Does Enanta Pharmaceuticals Inc have strong fundamentals2026 Big Picture & Weekly Setup with High ROI Potential - baoquankhu1.vn
ENTA Stock Price, Quote & Chart | ENANTA PHARMACEUTICALS INC (NASDAQ:ENTA) - ChartMill
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in - PharmiWeb.com
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026 - Business Wire
Trading Systems Reacting to (ENTA) Volatility - Stock Traders Daily
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Enanta Pharmaceuticals (NASDAQ:ENTA) Shares Pass Below 200 Day Moving AverageShould You Sell? - MarketBeat
Jefferies reiterates Enanta Pharmaceuticals stock rating on patent case By Investing.com - Investing.com Canada
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI) - BioSpace
Gains Report: Why is Enanta Pharmaceuticals Inc stock going upMarket Growth Summary & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026 - businesswire.com
Enanta (NASDAQ:ENTA) Biotech Momentum Builds Across Nasdaq Index - Kalkine Media
Enanta Pharmaceuticals (NASDAQ:ENTA) Now Covered by Rodman & Renshaw - Defense World
Vanguard disaggregates holdings; reports 0 shares of Enanta (ENTA) - Stock Titan
Enanta Advances Federal Circuit Appeal in Paxlovid Patent Case - TipRanks
Federal Circuit schedules oral argument in Enanta’s patent case against Pfizer - in.investing.com
Enanta Pharmaceuticals (NASDAQ:ENTA) Now Covered by Analysts at Rodman & Renshaw - MarketBeat
Federal Circuit schedules oral argument in Enanta’s patent case against Pfizer By Investing.com - za.investing.com
Aug Catalysts: Can Enanta Pharmaceuticals Inc be recession proofM&A Rumor & Entry Point Confirmation Alerts - baoquankhu1.vn
How Enanta Pharmaceuticals Inc. (ENTA) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Below Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Weekly Recap: How sensitive is Enanta Pharmaceuticals Inc to inflation2026 Movers & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Trend Recap: Can Enanta Pharmaceuticals Inc sustain earnings growth2026 Technical Patterns & Smart Allocation Stock Tips - baoquankhu1.vn
ENTA SEC FilingsEnanta Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Free cash flow per share of Enanta Pharmaceuticals, Inc. – FWB:9EP - TradingView
Enanta Pharmaceuticals Pitches RSV Phase 3 Plans, Expands Oral Immunology Pipeline at Citizens Conference - MarketBeat
Commodore Capital LP Buys New Holdings in Enanta Pharmaceuticals, Inc. $ENTA - MarketBeat
(ENTA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Enanta Shareholders Approve Board Elections and Equity Plan - The Globe and Mail
Enanta (NASDAQ: ENTA) director receives 20,000-share stock option grant - Stock Titan
Enanta (ENTA) director Lesley Russell receives stock options on 20,000 shares - Stock Titan
Enanta (ENTA) director awarded stock option for 20,000 shares - Stock Titan
Enanta (ENTA) awards 20,000 stock options to director Yujiro S. Hata - Stock Titan
Enanta (ENTA) director receives grant of 20,000 options at $14.17 - Stock Titan
Enanta (NASDAQ: ENTA) awards director 20,000-share stock option grant - Stock Titan
Enanta Pharmaceuticals presents data for KIT inhibitor EDP-978 - BioWorld MedTech
Aug Patterns: Does Enanta Pharmaceuticals Inc have strong fundamentals2026 Market WrapUp & Reliable Volume Spike Alerts - baoquankhu1.vn
Shareholders of Enanta (NASDAQ: ENTA) back equity plan expansion - Stock Titan
Enanta Pharmaceuticals at The Citizens Life Sciences Conference: Strategic Pipeline Advances - Investing.com Canada
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Quarterly Risk: Can Enanta Pharmaceuticals Inc reach all time highs this yearJuly 2025 Analyst Calls & Capital Efficiency Focused Ideas - baoquankhu1.vn
Is Enanta Pharmaceuticals Inc. stock resilient to inflationTrend Reversal & Free Expert Approved Momentum Trade Ideas - Naître et grandir
Enanta Pharmaceuticals (NASDAQ:ENTA) Share Price Passes Above 200-Day Moving AverageHere's Why - MarketBeat
Enanta Pharmaceuticals Inc (ENTA) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):